PURPOSE OF REVIEW Biomarkers of cardiac fibrosis closely track the disease state that gives rise to heart failure. The purpose of this review is to highlight recent data on the use of soluble ST2, galectin-3, and procollagen, three markers of cardiac fibrosis, for aiding with prognostication, and to explore the use of these biomarkers for guiding therapy. RECENT FINDINGS Soluble ST2, galectin-3, and procollagen are prognostic in both acute and chronic heart failure, and data are emerging as to their potential uses for guiding therapies. Mortality benefit from exercise, cardiac resynchronization therapy, statin use, as well as anti-fibrotic therapies such as aldosterone antagonism may vary based upon levels of these fibrosis markers. Soluble ST2, galectin-3, and procollagen provide independent prognostic information for heart failure morbidity and mortality. Markers of cardiac fibrosis may also help identify the subsets of patients who are most likely to benefit from various therapies. However, further studies are needed prior to formalizing individual patient care algorithms guided by fibrosis biomarkers.

中文翻译：

---

可溶性ST2和可溶性纤维化标记物：对预后和指导治疗的新兴作用。

审查的目的心脏纤维化的生物标志物密切跟踪引起心力衰竭的疾病状态。这篇综述的目的是重点介绍有关心脏纤维化的三种标志物可溶性ST2，半乳凝素-3和胶原蛋白原的使用的最新数据，以帮助预后，并探讨这些生物标志物在指导治疗中的用途。最近的发现可溶性ST2，半乳凝素3和胶原蛋白原对急性和慢性心力衰竭均具有预后作用，有关其指导治疗的潜在用途的数据正在涌现。运动，心脏再同步疗法，他汀类药物的使用以及抗纤维化疗法（如醛固酮拮抗作用）的死亡率可能会因这些纤维化指标的水平而异。可溶性ST2，半乳凝素3，和胶原蛋白为心力衰竭的发病率和死亡率提供独立的预后信息。心脏纤维化的标志物也可能有助于确定最有可能从各种疗法中受益的患者亚组。但是，在正式确定由纤维化生物标记物指导的个体患者护理算法之前，需要进行进一步的研究。